Protara Therapeutics (NASDAQ:TARA) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald started coverage on shares of Protara Therapeutics (NASDAQ:TARA) in a research report issued on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.

A number of other research firms have also weighed in on TARA. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th. Lifesci Capital started coverage on Protara Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $22.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Protara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Trading Down 1.2 %

Shares of NASDAQ TARA opened at $4.02 on Friday. The firm has a market capitalization of $82.93 million, a P/E ratio of -1.43 and a beta of 1.69. The firm’s 50-day moving average price is $4.45 and its 200-day moving average price is $3.46. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. Equities research analysts forecast that Protara Therapeutics will post -3.32 EPS for the current year.

Institutional Trading of Protara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TARA. XTX Topco Ltd bought a new stake in Protara Therapeutics in the third quarter worth about $60,000. HBK Investments L P bought a new position in Protara Therapeutics during the fourth quarter valued at $106,000. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics during the 4th quarter worth $110,000. Dimensional Fund Advisors LP purchased a new stake in Protara Therapeutics in the 4th quarter worth about $111,000. Finally, Bailard Inc. bought a new stake in Protara Therapeutics in the 4th quarter valued at about $157,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.